Related Experiment Video
Updated: Oct 5, 2025

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
Published on: January 24, 2016
Influenza D virus Matrix protein 1 restricts the type I interferon response by degrading TRAF6
Zhaoshan Chen1, Yan Zeng1, Yanli Wei1
1State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730046, PR China.
Abstract:
Influenza D virus (IDV) is an emerged virus that was first isolated in 2011 in the United States. Evidence suggests that IDV has broad host tropism and zoonotic potential. However, the immune evasion mechanism of IDV has not been explored. In the present study, we identified that the Matrix protein 1 (M1) of IDV is a negative regulator of virus- or RIG-IN-triggered type I interferon induction. Co-immunoprecipitation experiments revealed that M1 specifically interacts with tumor necrosis factor receptor associated factor 6 (TRAF6) and potentiates its proteasomal degradation by promoting K48-linked polyubiquitination. Moreover, we discovered that E3 ubiquitin ligase KEAP1 is recruited by M1 to catalyze K48-linked polyubiquitination of TRAF6, and promotes TRAF6 destabilization. Consequently, the degradation cascade mediated by M1 blocks RIG-I-TRAF6 mediated interferon signaling. Taken together, our findings reveal a negative regulatory role for the IDV M1 in the type І interferon pathway.
Related Concept Videos
Leaky Scanning
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
TGF - β Signaling Pathway
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

